Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis

Published:2018-06-10 Issue:9 Volume:20 Page:2255-2263
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Andreadis Panagiotis¹^ORCID,Karagiannis Thomas¹^ORCID,Malandris Konstantinos¹^ORCID,Avgerinos Ioannis¹^ORCID,Liakos Aris¹^ORCID,Manolopoulos Apostolos¹^ORCID,Bekiari Eleni¹^ORCID,Matthews David R²³^ORCID,Tsapas Apostolos¹³^ORCID

Affiliation:

1. Clinical Research and Evidence-Based Medicine Unit, Second Medical Department; Aristotle University of Thessaloniki; Thessaloniki Greece

2. Oxford Centre for Diabetes, Endocrinology and Metabolism; Churchill Hospital; Oxford UK

3. Harris Manchester College; University of Oxford; Oxford UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13361/fullpdf

Reference35 articles.

1. Food and Drug Administration (FDA) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf

2. European Medicines Agency (EMA) 2017 http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion-Initial_authorisation/human/004174/WC500240373.pdf. Accessed February 20

3. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial;Davies;JAMA,2017

4. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial;Sorli;Lancet Diabetes Endocrinol.,2017

5. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial;Ahrén;Lancet Diabetes Endocrinol.,2017

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study;eClinicalMedicine;2024-09

2. Newer Outpatient Diabetes Therapies and Technologies;Medical Clinics of North America;2024-09

3. Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality;JAMA Network Open;2024-08-20

4. The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study;Frontiers in Endocrinology;2024-08-14

5. Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys;Psychopharmacology;2024-06-17